Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2022 | Acalabrutinib in combination with umbralisib and ublituximab in previously untreated MCL

Geoffrey Shouse • 12 Dec 2022
ASH 2022
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma Acalabrutinib Antibodies Ublituximab Umbralisib

In this video, Geoffrey Shouse, DO, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, shares some results from a Phase II study evaluating the safety and efficacy of acalabrutinib in combination with umbralisib and ublituximab (AU2) for patients with previously untreated mantle cell lymphoma (MCL; NCT04783415). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Kite Pharma: Speakers Bureau; Beigene Inc USA: Honoraria.

More from Geoffrey Shouse

The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL 0:43
The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
Geoffrey Shouse • 11 Dec 2023
Novel approaches in Richter’s transformation: CAR-T and bispecifics 0:58
Novel approaches in Richter’s transformation: CAR-T and bispecifics
Geoffrey Shouse • 11 Dec 2023
Phase I study of copanlisib plus venetoclax in R/R DLBCL 0:51
Phase I study of copanlisib plus venetoclax in R/R DLBCL
Geoffrey Shouse • 11 Dec 2023
First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL 0:58
First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL
Geoffrey Shouse • 11 Dec 2023

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals